MURAL ONCOLOGY, INC.

In 2025, genetic validation will be crucial in cardiovascular R&D, investors will focus on proven science, and patients will be more active in healthcare. Precision medicine and genetic data will drive drug development, with data becoming the gold standard for investments. Real-world data (RWD) integration will transform clinical trials, enhancing patient control over medical records.

Trump's deregulatory economic policy and favorable seasonal period for the economy have analysts optimistic about market growth. Raymond James highlights Mural Oncology (MURA) and Disc Medicine (IRON) as stocks with significant upside potential, with MURA potentially gaining nearly 440% and IRON around 70%.

Neoadjuvant nivolumab with or without ipilimumab induced immune activation in early TNBC, achieving pathologic complete responses. Cetuximab improved 2-year disease-free survival in advanced head and neck cancer. Subcutaneous pembrolizumab with berahyaluronidase alfa plus chemotherapy was noninferior to intravenous pembrolizumab. Former Celgene shareholders filed a $6.7 billion lawsuit against Bristol Myers Squibb. The BMJ retracted and updated an article on weight loss and cancer. Buxton Helmsley urged a Senate committee to investigate alleged FDA data fraud. Preoperative chemotherapy followed by surgery and radiotherapy led to a 100% clinical benefit rate in rare head and neck squamous cell carcinoma. The FDA updated fludarabine phosphate labeling. The American Lung Association highlighted improved 5-year lung cancer survival. Overdiagnosis may contribute to rising pancreatic cancer rates in young adults. History of endometriosis or uterine fibroids increased risk of premature death due to gynecologic cancers. Modified antioxidant therapy reduced chronic pain in cancer patients. Nemvaleukin alfa plus pembrolizumab achieved durable responses in several solid tumors.

Nemvaleukin alfa showed promising antitumor activity and tolerability in ARTISTRY-1 trial, with notable responses in platinum-resistant ovarian cancer and mucosal melanoma, supporting ongoing registrational trials with data expected in Q1/Q2 2025.

Mural Oncology published data from ARTISTRY-1 trial showing nemvaleukin's tolerability and antitumor activity in advanced solid tumors, including durable responses in platinum-resistant ovarian cancer.

Mural Oncology reports financial results for Q3 2024, updates on late-stage trials of nemvaleukin alfa, and plans for IL-18 and IL-12 programs, with data readouts expected in 2025.

Checkpoint inhibitors, like Merck’s Keytruda, have revolutionized immuno-oncology, but response rates have plateaued at 30%. A decade of research has led to a deeper understanding of cancer biology, setting the stage for a second wave of IO therapies, potentially driven by smaller biotech companies. This new wave will explore additional pathways beyond PD-1, with bispecifics and ADCs showing promise. The potential for cytokines and multi-specific antibodies offers hope for more effective, targeted cancer treatments.

Mural Oncology's virtual Investor Day highlighted progress in its lead candidate, Nemvaleukin, an engineered IL-2 cytokine showing promising efficacy in combination with pembrolizumab. The phase 3 ARTISTRY-7 trial for platinum-resistant ovarian cancer and phase 2 ARTISTRY-6 trial for mucosal melanoma are fully enrolled, with key data expected in early to mid-2025. The company also discussed its IL-18 program, with an IND submission planned for Q4 2025. Mural's fair value estimate is $12.00 per share, with a 'Long-Term Buy' rating and an implied upside of 293.4%.

Mural Oncology to host virtual Investor Day, sharing insights on nemvaleukin trial design, statistical assumptions, and progress. Key data readouts for nemvaleukin in platinum-resistant ovarian cancer and mucosal melanoma expected in late Q1/early Q2 2025. IND submission for Mural’s IL-18 program planned for Q4 2025.